Investigational New Drug
USFDA program and procedures
Investigational New Drug
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. Regulations are primarily at 21 CFR 312. Similar procedures are followed in the European Union, Japan, and Canada due to regulatory harmonization efforts by the International Council for Harmonisation.
Read on Wikipedia · Image en:User:Sponge, CC BY-SA 3.0
Open boosters, collect cards and trade them. Free to play.
Play for free